Microbiome therapeutics are aimed at engineering the gut microbiome using additive, subtractive, or modulatory therapy with an application of native or engineered microbes, antibiotics, bacteriophages, and bacteriocins. This approach could overcome the limitation of conventional therapeutics by providing personalized, harmonized, reliable, and sustainable treatment. Its huge economic potential has been shown in the global therapeutics market. According to market research study published by Gen Consulting Company, the market size of the global microbiome therapeutics sector is expected to rise by USD 974 million with a CAGR of 27.8% by the end of 2028.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global microbiome therapeutics market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the microbiome therapeutics industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the strategy, target therapy area, and region. The global market for microbiome therapeutics can be segmented by strategy: additive, modulatory, subtractive. According to the research, the additive segment had the largest share in the global microbiome therapeutics market. Microbiome therapeutics market is further segmented by target therapy area: gastrointestinal tract diseases (GIT), infections, metabolic diseases, cancer, others. In 2021, the GIT segment made up the largest share of revenue generated by the microbiome therapeutics market. Based on region, the microbiome therapeutics market is segmented into: Asia Pacific, Europe, North America, Rest of the World (RoW).

By strategy:
– additive
– modulatory
– subtractive

By target therapy area:
– gastrointestinal tract diseases (GIT)
– infections
– metabolic diseases
– cancer
– others

By region:
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)

The report explores the recent developments and profiles of key vendors in the Global Microbiome Therapeutics Market, including 4D Pharma plc, Assembly Biosciences, Inc., BiomX Inc., Evelo Biosciences, Inc., Kaleido Biosciences, Inc., Sanofi S.A., Seres Therapeutics, Inc., Synlogic, Inc., Synthetic Biologics, Inc., among others.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period
This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report
– To analyze and forecast the market size of the global microbiome therapeutics market.
– To classify and forecast the global microbiome therapeutics market based on strategy, target therapy area, region.
– To identify drivers and challenges for the global microbiome therapeutics market.
– To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global microbiome therapeutics market.
– To identify and analyze the profile of leading players operating in the global microbiome therapeutics market.

Why Choose This Report
– Gain a reliable outlook of the global microbiome therapeutics market forecasts from 2022 to 2028 across scenarios.
– Identify growth segments for investment.
– Stay ahead of competitors through company profiles and market data.
– The market estimate for ease of analysis across scenarios in Excel format.
– Strategy consulting and research support for three months.
– Print authentication provided for the single-user license.